Five Prime Cancels Fourth Quarter and Full-Year 2020 Financial Results Conference Call

Rhea-AI Summary

Five Prime Therapeutics, Inc. (NASDAQ: FPRX) has announced the cancellation of its fourth quarter and full year 2020 earnings call, originally set for March 10, 2021. This decision follows the recent agreement for Amgen Inc. to acquire the company. The financial results for the fourth quarter and full year 2020 will be disclosed in the upcoming Form 10-K filing with the SEC. Five Prime is focused on developing novel cancer therapies and has established collaborations with major pharmaceutical companies.

Positive

• Agreement for acquisition by Amgen Inc., indicating a strategic move towards consolidation and potential for growth.
• Focus on developing breakthrough cancer therapies, which may enhance future prospects.

Negative

• Cancellation of the earnings call may create uncertainty among investors.
• Acquisition could lead to changes in strategic direction, affecting current stakeholders.

Five Prime Therapeutics, Inc. (NASDAQ: FPRX) announced today that it has canceled its fourth quarter and full year 2020 earnings conference call, which was previously scheduled for Wednesday, March 10, 2021 at 1:30 p.m. PT / 4:30 p.m. ET.

The cancellation is the result of the company’s announcement on March 4, 2021 that it has entered into an agreement under which Amgen Inc. will acquire Five Prime Therapeutics. Five Prime will issue its fourth quarter and full-year 2020 financial results in its Form 10-K that it will file with the Securities and Exchange Commission.

About Five Prime Therapeutics

Five Prime is a clinical stage biotechnology company relentlessly focused on rewriting cancer. By tackling the tough scientific questions and untapped pathways, we aim to offer new hope by developing novel, breakthrough therapies that have potential to alter the course of disease in cancers with few treatment options. This vision is what defines us and guides our research, clinical development and partnerships. To build a better tomorrow for people with cancer, we are teaming up with patients, physicians, scientists, and industry partners to make a meaningful difference in patients’ lives. Five Prime collaborates with leading global pharmaceutical companies and has therapies in pre-clinical and clinical development. For more information, please visit www.fiveprime.com.

Source: Five Prime Therapeutics, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210309006037/en/

FAQ

What led to the cancellation of Five Prime Therapeutics' earnings call?

The cancellation was due to the announcement of Amgen Inc.'s acquisition of Five Prime.

When will Five Prime Therapeutics release its financial results for 2020?

The financial results will be issued in their Form 10-K filing with the SEC.

What is the significance of Amgen's acquisition of Five Prime Therapeutics?

The acquisition may provide new resources and opportunities for Five Prime's cancer therapies.

What is Five Prime Therapeutics' focus in the biotechnology sector?

The company is dedicated to developing novel therapies for cancer with limited treatment options.